Two Sigma Investments LP decreased its position in Organigram Holdings Inc. (NASDAQ:OGI - Free Report) by 59.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 130,477 shares of the company's stock after selling 189,007 shares during the quarter. Two Sigma Investments LP owned 0.10% of Organigram worth $210,000 at the end of the most recent quarter.
A number of other institutional investors also recently added to or reduced their stakes in OGI. Two Sigma Securities LLC purchased a new position in shares of Organigram in the 4th quarter valued at $26,000. Oxford Asset Management LLP acquired a new position in Organigram in the fourth quarter valued at $50,000. Cubist Systematic Strategies LLC grew its holdings in shares of Organigram by 210.7% during the fourth quarter. Cubist Systematic Strategies LLC now owns 45,095 shares of the company's stock worth $73,000 after purchasing an additional 30,583 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Organigram by 13.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 359,739 shares of the company's stock worth $579,000 after purchasing an additional 43,721 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in shares of Organigram during the fourth quarter worth about $1,153,000. Hedge funds and other institutional investors own 34.63% of the company's stock.
Organigram Trading Down 4.8%
Shares of NASDAQ OGI traded down $0.07 during trading hours on Friday, reaching $1.40. The stock had a trading volume of 855,472 shares, compared to its average volume of 657,267. Organigram Holdings Inc. has a fifty-two week low of $0.85 and a fifty-two week high of $2.08. The firm has a 50-day moving average of $1.20 and a 200-day moving average of $1.31. The firm has a market cap of $187.44 million, a price-to-earnings ratio of -3.68 and a beta of 1.37.
About Organigram
(
Free Report)
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
Read More
Before you consider Organigram, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.
While Organigram currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
